ITCI Quote, Trading Chart, Intra-Cellular Therapies Inc.

$34.525 Last:

0.25% Change Percent:

$34.55 Open:

$34.525 Previous Close:

$35.06 High:

$33.505 Low:

183,801 Volume:

03/03/2021 12:15:30 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-03-03	34.55	34.525	35.06	33.505	183,801
2021-03-02	34.89	34.44	36.05	34.39	378,742
2021-03-01	36.6	34.97	36.91	34.765	438,259
2021-02-26	33.6	35.43	36.05	33.5	871,404
2021-02-25	36.1	35.68	37.5199	34.28	680,116
2021-02-24	37.01	37.84	38.14	36.86	424,535
2021-02-23	38.5	36.89	38.96	35.26	927,488
2021-02-22	39.98	38.97	40.005	38.6	843,528
2021-02-19	39	39.51	40	38.715	1,039,343
2021-02-18	38.83	39.02	39.4	38.05	541,780
2021-02-17	38.92	38.98	39.28	37.56	523,097
2021-02-16	39.27	38.98	39.62	37.975	695,421
2021-02-15	38.94	39.08	39.59	38.53	857,170
2021-02-12	38.94	39.08	39.59	38.53	857,161
2021-02-11	37.99	39.05	39.47	37.85	734,735
2021-02-10	37.74	37.7	38	36.255	392,499
2021-02-09	38.2	37.53	38.77	37.235	709,298
2021-02-08	36.19	38.085	38.09	35.54	863,847
2021-02-05	35.04	35.76	35.84	33.9325	694,938
2021-02-04	34.83	34.815	35.25	33.73	610,075

Stock Information

Intra-Cellular Therapies Inc. Company Name:

ITCI Stock Symbol:

NASDAQ Market:

Get ITCI Alerts

News, Short Squeeze, Breakout and More Instantly...

ITCI - Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript

Image source: The Motley Fool. Intra-Cellular Therapies Inc (NASDAQ: ITCI) Q4 2020 Earnings Call Feb 25, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Tran...
ITCI - Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively....
ITCI - Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284

ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations. Phase 1 single ascending dose and multiple ascend...